A Comprehensive Pipeline for Cancer Neoantigen Immunogenicity Prediction

Kaixuan Diao,Jing Chen,Tao Wu,Xuan Wang,Guangshuai Wang,Xiaoqin Sun,Xiangyu Zhao,Chenxu Wu,Jinyu Wang,Huizi Yao,Casimiro Gerarduzzi,Xue-Song Liu

DOI: https://doi.org/10.3390/ijms231911624

IF: 5.6

2022-10-02

International Journal of Molecular Sciences

Abstract:Neoantigens derived from somatic DNA alterations are ideal cancer-specific targets. In recent years, the combination therapy of PD-1/PD-L1 blockers and neoantigen vaccines has shown clinical efficacy in original PD-1/PD-L1 blocker non-responders. However, not all somatic DNA mutations result in immunogenicity among cancer cells and efficient tools to predict the immunogenicity of neoepitopes are still urgently needed. Here, we present the Seq2Neo pipeline, which provides a one-stop solution for neoepitope feature prediction using raw sequencing data. Neoantigens derived from different types of genome DNA alterations, including point mutations, insertion deletions and gene fusions, are all supported. Importantly, a convolutional neural network (CNN)-based model was trained to predict the immunogenicity of neoepitopes and this model showed an improved performance compared to the currently available tools in immunogenicity prediction using independent datasets. We anticipate that the Seq2Neo pipeline could become a useful tool in the prediction of neoantigen immunogenicity and cancer immunotherapy. Seq2Neo is open-source software under an academic free license (AFL) v3.0 and is freely available at Github.

biochemistry & molecular biology,chemistry, multidisciplinary